Partnering opportunity

Novel engineered non-liposomal nanovesicles and their use in nucleic acid delivery

Summary

A Spanish biomedical research networking center has developed novel engineered non-liposomal nanovesicles, here named QS, an innovative tool for nucleic acid delivery, allowing the transported nucleic acid to perform its activity in the cytosol, and to be used for the treatment of cancer, looking to establish license, research cooperation or technical cooperation agreements.

Partner sought

Patent ready for licensing-out. The research center is seeking industrial partners, either from the Biotech or Pharma sectors, to: - enter into preclinical R&D collaboration (in vitro and/or in vivo drug testing) through research cooperation agreements. - Further development until clinical proof-of-concept via license or technical cooperation agreements.

Description

This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions as universities, hospitals and technological centers distributed around the country. RNA therapeutics is an emerging field with a promising number of targets around all the transcriptome, which includes small RNAs like small interfering RNA (siRNA), microRNA (miRNA), among others. Although, the RNA based-therapies may be an alternative to chemoresistant tumors, the in vivo administration is still a challenge in the field, due to the rapid clearance and degradation of small RNAs in the bloodstream. As of today, nanomedicine promises the precise delivery of drugs to disease sites (i.e. tumours) with reduced off-target toxicities. Liposomal nanovesicles are one of the most promising candidates for drug delivery in nanomedicine. However, these liposomal-based medicinal products still present unsolved drawbacks such as poor colloidal stability, short half-life when administered in the blood circulation, nonspecific bio-distribution and modification of endogenous RNA machinery. Novel engineered non-liposomal nanovesicles (QS) have been developed to overcome some of the previously stated problems related to application of RNA based therapeutics in the treatment of human diseases, such as cancer.

Advantages and innovations

The new QS is an innovative tool for nucleic acid delivery, allowing the transported nucleic acid to perform its activity inside the cell (cytosol). QS may be used in the development of RNA (Ribonucleic acid) based therapeutics for the treatment of human diseases, such as cancer. The engineered QS are composed by preservatives and sterol derivates, all elements FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) approved. These QS have shown great in vitro transfection efficiencies and good biocompatibility, comparable to other commercial transfection reagents (e.g. Lipofectamine® 2000) and also potent anti-tumoural activity in neuroblastoma cell lines. Development of a pharmaceutical composition comprising a therapeutically effective amount of the nanovesicle and a pharmaceutically acceptable excipient or vehicle can be carried out. The nanovesicle or the pharmaceutical composition can be used as a medicament for the treatment of diseases that use nucleic acids as therapeutic agent (e.g. cancer, in neuroblastoma) These QS can be also used as a bioimaging and theranostic tool.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company